F M Investments LLC Invests $2.06 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

F M Investments LLC bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 16,924 shares of the biotechnology company's stock, valued at approximately $2,058,000.

Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Sarepta Therapeutics by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock valued at $1,104,701,000 after purchasing an additional 117,904 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Sarepta Therapeutics by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company's stock worth $207,538,000 after acquiring an additional 9,999 shares during the last quarter. Norges Bank acquired a new position in shares of Sarepta Therapeutics during the fourth quarter valued at $126,315,000. Erste Asset Management GmbH boosted its holdings in Sarepta Therapeutics by 11.3% in the fourth quarter. Erste Asset Management GmbH now owns 708,248 shares of the biotechnology company's stock valued at $86,116,000 after acquiring an additional 72,183 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its position in shares of Sarepta Therapeutics by 2.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 639,332 shares of the biotechnology company's stock worth $77,736,000 after buying an additional 14,444 shares during the period. Institutional investors own 86.68% of the company's stock.

Remove Ads

Sarepta Therapeutics Stock Down 0.4 %

SRPT traded down $0.21 during trading on Tuesday, reaching $54.42. 2,215,088 shares of the stock were exchanged, compared to its average volume of 1,397,937. The stock has a market cap of $5.28 billion, a P/E ratio of 43.54 and a beta of 0.93. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The stock's 50 day moving average price is $86.82 and its two-hundred day moving average price is $109.61. Sarepta Therapeutics, Inc. has a twelve month low of $48.01 and a twelve month high of $173.25.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SRPT shares. Cantor Fitzgerald restated an "overweight" rating and set a $163.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Morgan Stanley dropped their price target on Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating on the stock in a research report on Friday. Needham & Company LLC decreased their price objective on Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating for the company in a research report on Thursday, April 3rd. HC Wainwright upgraded shares of Sarepta Therapeutics from a "sell" rating to a "neutral" rating and set a $75.00 target price on the stock in a report on Wednesday, April 2nd. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a report on Wednesday, March 19th. Six research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $161.83.

Insider Transactions at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 7.70% of the stock is owned by company insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.